MedTrace Logo

Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis

NCT07243366 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-11-21

No results posted yet for this study

Summary

This study is a single-center, prospective, nonrandom, single-arm trial.

Conditions

  • Refractory Myasthenia Gravis

Interventions

DRUG

CD19-CAR-NK Cells Injection

Allogeneic CD19-CAR-NK cells will be administered intravenously at a fixed dose, once every two weeks for a total treatment duration of 24 weeks.

Sponsors & Collaborators

  • Guangdong ProCapZoom Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-25
Primary Completion
2027-06-30
Completion
2027-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07243366 on ClinicalTrials.gov